The investigational vasopeptidase inhibitor omapatrilat is as effective as enalapril in preventing major adverse cardiac outcomes in patients with moderate to severe heart failure, but failed to show superiority, said Milton Packer, MD.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

No advantage to omapatrilat over enalapril in heart failure . . .

Newsletter